Nuclear factor kappa B expression in non-small cell lung cancer

Biomed Pharmacother. 2023 Sep 14;167:115459. doi: 10.1016/j.biopha.2023.115459. Online ahead of print.ABSTRACTIn this mini-review, we discuss the role of NF-κB, a proinflammatory transcription factor, in the expression of genes involved in inflammation, proliferation, and apoptosis pathways, and link it with prognosis of various human cancers, particularly non-small cell lung cancer (NSCLC). We and others have shown that NF-κB activity can be impacted by post-translational S-glutathionylation through reversible formation of a mixed disulfide bond between its cysteine residues and glutathione (GSH). Clinical data analysis showed that high expression of NF-κB correlated with shorter overall survival (OS) in NSCLC patients, suggesting a tumor promotion function for NF-κB. Moreover, NF-κB expression was associated with tumor stage, lymph node metastasis, and 5-year OS in these patients. NF-κB was over-expressed in the cytoplasm of tumor tissue compared to adjacent normal tissues. S-glutathionylation of NF-κB caused negative regulation by interfering with DNA binding activities of NF-κB subunits. In response to oxidants, S-glutathionylation of NF-κB also correlated with enhanced lung inflammation. Thus, S-glutathionylation is an important contributor to NF-κB regulation and clinical results highlight the importance of NF-κB in NSCLC, where NF-κB levels are associated with unfavorable prognosis.PMID:37716117 | DOI:10.1016/j.biopha.2023.115459

Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 16, 2023 Category: Drugs & Pharmacology Authors: Leilei Zhang Claudia M Ludden Alexander J Cullen Kenneth D Tew Andr é Luís Branco de Barros Danyelle M Townsend Source Type: research